leadership through dr. butler and hundreds of others that are true professionals in how to manage and second, we went to private industry. why? because private industry knows how to do this. they do it every day. they do it quietly. they do it professionally. they do it with expertise. vaccines and medicines flowing throughout our country every single day. who is doing it? private industry. we went to them. we collaborated with them. we took their good ideas,we put them in our plan. the cdc integrated, synchronized their capabilities and capacity of industry to ensure that we have a well-nested plan for distribution. right? what was the last thing?

key to our success. it's not our plan that needs to be implemented perfectly. it's the governor's plans that we want to enable, that we want to empower, that we want to make sure that we can execute according to their priorities and guidance. that i know their space. they know their people. they are being informed by highly professional medical personnel that know their people and their states. our position is to enable them. so it is this trifecta, the cdc, commercial industry and the governors and their states that will make us successful at the end of the day. trust me, it's about collaboration, it's about unity of effort. it's not about command and control. this is what the operation has

been able to synchronize and integrate. so as said earlier, right? what is our goal? our goal is upon eua, emergency use authorization, which will be determined by the fda. we will start moving vaccines within 24 hours. we will move them throughout the entire united states of america. 50 states, eight territories, six major cities. five federal agencies. we know, right, based on the allocations available from pfizer vaccine and our allocation process was by pro rata to the population of each state, territory or city above the age of 18 to ensure fair and equitable distribution of vaccine every day. we know that for pfizer vaccine based on our allocation, we know

exactly as of last friday where the states want their vaccine distributed to. we know the locations, our address. we know the populations based on the amounts that they want at each location. we know this as a fact. we're already sharing this information with industry, which i'll talk about in a minute, what they're going to do with it so they can plan package and prepare and distribute. this week we're working on the moderna vaccine initial allocations with the states. by this friday we will have all the locations for the moderna vaccine allocation from the states. we'll know where they want it and how much they want it. so within a one-week period, we've been able to accumulate, process and inform and collaborate where the vaccine is going to. key to our success.

so now we have eua, we have the information we need, where it's going, how much is going. so how is it going? first, the pfizer vaccine is depicted up front half of the chart. their goal is to deliver vaccine to the right side of the chart on all of those places and locations we want it to go to. pfizer vaccine -- pfizer has chosen to do their own delivery of vaccine, right? in collaboration with us, our priorities to distribution capabilities. right? fed ex and ups. right? they will distribute the fed ex and ups and fed ex and ups will break down the vaccine by location and then distribute it to the final locations accordingly. the moderna vaccine is going a little bit differently. moderna chose to have a distributor come in and help them mckesson will take

responsibility for that. they're going to break down the vaccine. they will repackage it, then they will distribute it through fed ex and ups down through the final administration sites as directed by the governors. at the end of the day, whether it's pfizer or moderna, our capability and capacity is something that we know how to do and we know how to track and how to implement it and how to make sure that the vaccine is delivered, delivered safely, it is delivered to ensure the stability of the vaccine and it is delivered securely to the locations that we said. right? this is why we put this all together. it will be a herculean task. but i'm confident, as i said, the planning by the cdc, the collaboration by our partners, mckesson, fed ex, ups, cvs,

walgreen's, that we can execute the vaccine efficiently and more importantly effectively. as we start to deliver the vaccine, we will be able to track every single vaccine from start to finish. we have worked in great collaboration with commercial industry. we have developed a capacity or capability to track every vaccine. we will see from point a to point b. we will understand how the vaccine is being administered in arms and we will continue to flow vaccine to support the use at the administration sites. the key is flow of available vaccine. we're not waiting for a montly cycle of delivery of vaccine. every day, every week that vaccine become as available, allocations will be provided to

the states and we will start and we will execute a predictable and consistent cadence of vaccine delivery. we will do that by providing allocations to the states. states will tell us where they want the vaccines to go and we will deliver the vaccines in accordance to the process that i told you. what is the greatness of this? it is about making sure that we get the initial doses out, following eua within 24 hours and then providing a steady cadence of vaccine so that planners can plan and then people who are going to have to administer understand the timing of administration where we can notify persons to come get shots and be available. it's the flow we're trying to create that will determine our success. i'm very excited about this. i'm very excited about the

amount of work that has gone into this. somebody said to me the other day, i heard there's eua coming about. are you going to start planning? i said start planning? we literally started planning as dr. slaoui talked about seven months ago. it was in parallel that we executed this. we assumed success so that we could get ahead of the problem. because of the great efforts by the cdc, the collaboration of commercial industry and the states herculean effort to plan for people to receive shots that we're going to be successful. so with that said, i will tell you, i am 100% confident that we will be able to implement this. with our collaboration of the trifecta there, we will be successful, and we will start to have shots in arms within 96

hours of eua. that's what i believe with all of my heart. and i am counting on it because i for one have told my mother, get the vaccine. i told my sons, get the vaccine. that's how confident i am in this. so i ask for you as dr. slaoui said at the end, right? all of us, the american people, we can beat this only together. right? we can do this if we do it together. right? be informed. right? don't be led. understand, do your research, hold yourself accountable to hearing both sides of the story and make an individual decision that is best for yourself and your family and your community. right? if we do that, we will be successful and we will defeat, right, the enemy, which is covid. so with that said, thank you, everybody, for your time.

it's a real pleasure. [applause] >> bill: this is really great stuff here. we're watching american history. we're watching medical history. operation warp speed. taking a bit of a victory lap and for good reason. i'm bill hemmer. good afternoon. we'll continue in this hearing for some time. we want to give our experts a chance to react. gentlemen, hello to you. welcome. doctor, i know you have a time crunch here. i think what the general said there is amazing. he said where is the end zone? the end zone is shots in the arm. it's happening in london today. it's going to happen here soon. what do you take away from the first hour, doc? >> yeah, bill, thanks for having me on. i can't help but feel really optimistic about what we've heard. look, there's a lot of planning that's gone into it. i'd love it if the first shots are going in in 24 to 48 hours

after third. the biggest issue is how many shots can we get, how many vaccines can we pull together. how quickly -- my guess it will take a few months till it gets out. this is progress. >> dr. mccarry, what is your take? >> the best news is we heard that the fda has found no serious adverse events. there were eight infections in the vaccine arm and 162 in the placebo arm. that is all the information we need. quite frankly, we should have been doing this a few weeks ago. this was data that was straightforward. it's amazing -- >> bill: we weren't we, doc? we talked about it a few days ago. why didn't we? >> well, i think there's a massive bureaucracy over there. it's the same reason your income tax form take a long time to fill out. could be streamlined. if the fda would have reduced the time in half -- forget about a 24-hour emergency meeting,

which they could have done to review this straightforward data. if they would have cut the time in half, that would have saved about 17,000 lives. 34,000 americans will have died during the time that the fda is reviewing the pfizer data after it was submitted. we could have done better. woo -- we're in a good spot. >> bill: the fda looks at the vaccine trial results and 34,000 died. it's a heavy thought. doctor, do you agree with his position that the fda, despite the speed could have gone faster? >> i'm a big fan of the doctor. i'm going to disagree vehemently here. here's the issue, bill. the bottom line is we could have just taken the data that pfizer presented and said, okay, that's good enough. the fda has a long track record of doing things the right way. they've had 150 people working day and night reviewing this data since pfizer submitted it.

i think -- i know the delay is not ideal, but the bottom line is it's worth getting it right. imagine if we had missed adverse events or rubber stamped this and found out bad things were happening, that would have been a disaster. i appreciate the delay, cost lives but getting it right is more important. >> bill: go ahead, doctor. >> there were no serious adverse events in any of the patients. so the 27-day hunt for an adverse event yielded nothing. that could have been done quicker. i agree. we shouldn't cut any corners but this could have been done quicker. my clinical background is that of a surgeon. we have to make life and death decisions all the time. when you don't make a decision, 2,000 americans are dying a day. 3s the point. >> bill: thanks to both of you. we're going to get inside the hearing. an ebb and flow of good news and bad news going back to last february.

certainly is a good news day. doctors, thanks so much. we're not listening to adam boller from the international finance corporation. this is how the fda evaluates the vaccine candidates. to the white house we go in washington. >> what that means by doing things parallel in a parallel manner, corners were not cut here. this is a vaccine that has gone through -- these vaccines are going through the large kinds of trials that we would expect from prophylactic vaccines that will be given to a large number of people. the average vaccine development program for the kind of prophylactic that we're talking about is 21,750 people enrolled. so this -- these programs went from 30,000 to 45,000, 44,000

individuals enrolled. that is a pretty nice size program. so that is giving us kind of the gold standard types of clinical trial program that we like to see for preventative vaccines. >> thank you, dr. marks. one question that is circling and dr. slaoui just talked about it is whether americans should take this vaccine. so let me ask that question to you. why should americans trust these vaccines? >> so the reason why i'm sitting here today and the reason why we're going through the process we're going through at fda is so that americans can trust a vaccine they're going to receive. the fda is known around the world for its regulatory rigor. we're one of the only regulators in the world where we don't just take the data handed to it from companies and look at it. we take the data listings, the

raw data and do analyses our serves on that. it's a group of over 150 people working right now at fda to go through and do these type of analyses to make sure that the vaccine is what it says it is. to make sure that we fully under the side effect profile, to understand -- sometimes we learn things that the manufacturers didn't even know about the vaccines by doing our analyses. so by doing that hard work, the folks are making sure that we've -- when it comes through this process, we're going to have a vaccine that has efficacy that we can trust, safety that we can trust and quality to trust, which is what americans deserve because all the people working at fda right now are thinking about this vaccine as if it's one that they want to take, they want to have their families take and then have our extended family in the united

states take. this is really important. we're only going to get there if we do this together, by taking vaccines together. this is a time where we have to rebuild our trust in vaccines. we hope by going to a advisory committee and the public view, where people will see the data being be it forth, a discussion against monk academic experts of the safety, effectiveness and the quality of these vaccines that people will see, nothing is being hidden, that these are vaccines that when we say at fda they're safe and effective, it means we've done our best job to make sure they're safe and effective for all of us to roll up our sleeves and take. >> thank you. could you expand a little bit on the clinical trial process? the size, the scope. give me a little sense of that. >> so these clinical trials that involve the randomization, so flipping a coin and putting one

to one person getting a placebo or inactive product versus the active vaccine. where we have 15,000 people in each arm to compare them means that we have a very large size trial, which not only lets us get to the efficacy quicker as dr. slaoui noted but give us a very nice size safety database. although normally we like to have longer follow up of individuals perhaps than we'll have right now, we're able to make up for that by following the people who are in the clinical trials for longer periods of time and by the fact that over the past ten years in the united states, we developed a very robust safety surveillance system which uses large databases during hundreds of millions of live to look at adverse events to make sure there are not problems coming up after the vaccines are given to people. we wouldn't let them out there in the first place if we thought

that there was any significant chance of that. but we are going to make sure by monitoring them that there are things that emerge as they're used. >> what happens next? i know obviously the fda will go through their process. a lot of people are expecting -- we hope for authorization. so assuming that that happens, assuming that you issued the eua, what happens next? >> so after an emergency use authorization is granted, we will -- several things will happen. but the advisory committee will make further recommendations about use of the vaccine. the vaccine will get in to the general's hands and we'll get it out there and activate our safive surveillance system. there will be in the coming months additional trials that will be done on these vaccines.

there's populations that we still don't have information on that we have to get information. children, pregnant women among them, that will get more data on these vaccines so we'll be able to ultimately hopefully by late spring start to get to the entire population and get to children so we can stop the entire covid cycle. >> once it gets to the general's hands -- what? that's it. one final question for you, dr. marks. expand a little bit on how important it is for every american to get this vaccine or not? feel free to say. >> i think it's really critical here to understand that what we're doing at fda is trying to make sure that people have the confidence to use vaccines. vaccines have been an incredible

public health advance. our agency has been regulating vaccines for over 100 years. since before -- the center for buy logics predated the food and drug administration. it was established in 1902 for anyone that wants a history lesson. we've been doing this for a while. the first or second bioligic was for a small pox vaccine. we have a good sense of what safety looks like for a vaccine. we've seen what vaccines can do. eliminated small pox. polio is something that nobody sees anymore in the united states because it's gone pretty much. even measles, we don't see because as long as we keep getting our children vaccinated, we don't have measles outbreaks in the united states. so it's a huge transformation from vaccines. we would not allow vaccines to go out there if they weren't

safe and effective. when we see safety signals, we deal with them. so it's critical here that we all trust in the outcome of this process because we all need to bring this crisis to an end together and getting vaccinated is kind of a first step there. you know, what we have right now is we can wear masks, we can cash our hands and stay social disstanced. with a vaccine, we can have it eradicated. that will only happen if a large fraction of eligible people take the vaccine. >> thank you, dr. marks. washington can be a difficult town. but you and your team and the group here show this is not a partisan effort. it's an american effort. as an american, i want to really say how much i appreciate all your work and your team's work. >> thanks very much. i have to say, i have an

incredible team of diverse individuals that are so committed to this, this they have worked tirelessly and they will continue to work tirelessly with these vaccines and additional vaccines till we have what we need to beat covid-19. >> thank you. [applause] >> bill: a little more from dr. peter marks from the fda. had the conversation there that q&a went down to the white house. the britts took the data about a week ago and giving vaccinations as we speak. the first woman, age 80. she was given a vaccination earlier today and patient number 1. back with the doctors. we wait for the white house to reset for the next segment, which is dr. admiral girrar. he will talk about how the vaccine will be distributed. on that point about distribution, why is it that

pfizer we're do it on its own and moderna will lean on the government to help them 0 it? why would there be a different when it comes to distribution? why wouldn't it be uniform? >> yeah, so pfizer has not taken money through operation warp speed. they made a decision early on, the ceo, that they were going to do this on their own. they weren't going to take that money. it gives them more freedom. my sense is they will coordinate. they're not going to go rogue on this. they want to have their own distribution plan and coordinate with the federal government but not be bound by the federal effort. >> bill: doctor, are you cool with that or is that something that you would have tried to rearrange also? >> no, look, we have to still with known distribution channels just as the doctors said. moderna decided to use mckesson. they've been distributing things a long time. i will say, bill, one piece of

guidance, what is if you've had natural immunity? i believe and my colleagues believe you should get in the back of the line. natural immunity may be as good as vaccinated immunity, could be better, could be worse. we don't know. we're not seeing reinfections. while we study natural immunity, let's give the supply constraint vaccine to those that haven't it. >> bill: i pulled from the piece that dr. slaoui said that this vaccine will be remain effective and safe. you have a six-month trial period. we know that so far. you want to comment? >> yeah, i don't disagree. we think that the natural infection probably gives you at least 10, 12 months of immunity, may be longer. we don't know. my guess is a vaccine will be at least as good as that and may be better. the way i think about this is if

you've been recently infected and recover, you don't need to run out and get the vaccine. obviously if you had an infection in march or april or you think you might have, i wouldn't use that too much to influeni influence your behavior. >> great information. we've been down this road and coming out with bad news. today is opposite of that. thank you, gentleman. stand by. i mentioned london, the u.k. giving the first doses of vaccine. i said she was 80. she was 90. greg palkot has that story now. hey, greg. >> bill, 90 going on 91. a real inspiration for everybody here, maybe around the world. we heard from the health minister, bill. in his word, today marks the start of the fight back against coronavirus. we're here in south london. it's the first injections, saw a visit from the u.k. prime minister johnson. 70 hospitals across the country started administering today.

the pfizer vaccine. u.k. is the first country as we've been saying in the world to use this widely tested, independently proven inoculation. there's challenges logistically of course, bill. the biggest one, you have to have stored and transported at minus 100 degrees fahrenheit. again, today we've heard the efficacy, 95%. why the britts rushed it out. listen to one top health official and what he said to me today. >> i wouldn't presume to say to other nations how they should do their vaccines, but i'm very clear. if it's good enough for the u.k., as far as i'm concerned, it's good enough for any other nation on earth. >> including the u.s.? >> including u.s. >> now, being vaccinated today, those giving out the injections front line health workers and yes, some over 80-year-olds included, 90-year-olds. listen to her take on it all.

>> so do take it. that's all i can say. if i can do it, so can you. >> if i can do it, so can you. good words to remember. back to you. >> bill: now back to the white house. this is admiral girard, this is the segment about -- that will explain how the vaccine will be distributed. you'll hear from a lot of people, too. ups, fed ex. drop in we go. back to this hearing at the white house now. >> they've been essential to bring ppe to distribute therapies like mono clonal an - anti-bodies and tests throughout the country. you'll hear the tip of the iceberg here. you heard their names. sean siemens, executive sponsor,

enterprise covid-19 program with mckesson. mark casper, chairman, president ceo of thermo fisher. wes wheeler, president of ups healthcare and richard smith, regional president of the americas for fed ex. so i'm going to lead with a few questions. my first that i'm going to direct at our colleague from mckesson. so let's talk generally, what is your role? you saw it on the board earlier. distributing vaccines including the needed supplies like syringes and needles. >> thank you for your leadership, admiraadmiral. i want to thank our partners. it's an honor and privilege for mckesson to play an important role. for those of you not familiar with mckesson, we're one of the largest healthcare suppliers in

the country. we deliver supplies to sites of care, hospitals, clinics, physicians. we also have an extensive background in vaccines. a proud supporter of the cdc vaccines for children for the past 13 years and we're the largest distributor of seasonal flu in the united states. we were also the centralized distributor for h1-n1 during that pandemic. so we have two primary roles. the first is centralized distributor of vaccines and the second is the producer of those ancillary supply kits. that's where i want to start. i have an example of the kit here that i can show on this crowded table. you can see, it comes in a box like this. we have produced enough of these kits to administer over 150 million doses of vaccine at this point. we've been well-at work manufacturing these kits the better part of the last 2 1/2

months. that kit right there will have enough supplies to administer 100 doses of vaccine, which is what will accompany most of the vaccine deliveries as part of this program. we're also doing another kit specific to pfizer which has the same supplies in it, needles, syringes, face masks, shields, face shields, alcohol wipes, swabs, et cetera. enough quantities to meet the pfizer minimum, which is 975 doses. so we will be shipping as you saw in the schematic the pfizer kits directly to the administration either in advance or at the same time to meet up with that pfizer vaccine. then we will be distributing that kit there, the 100 dose kit to our vaccine facilities so we can marry them up for the outside administration. that leads to the second role.

the centralized distributor. i want to point out a couple of quick things. we are not making any allocations decisions. that's done by the cdc, operation warped speed and their plans. we're program -- you heard 50,000 sites. this program is set up to ship to any number of sites. we can do hundreds of thousands of sites if necessary. we go anywhere that fed ex or ups is go, we can get a vaccine. so let me quickly talk about moderna and how that process, with. moderna will ship us a pallet of protect. we will ensure the temperature was maintained. we'll get into a specially designed freezer in one of our mu multiple facilities to take care of the vaccine. from there, we will take the

orders in from the cdc in terms of numbers of doses and where they need to be shipped. we'll pull those individual orders from the pallet, pack them into a specialized shipper, which is the smallest frozen shipper. these are custom designed for this program. then we will put in specialized cooling packs, we will not be using dry ice. so moderna and any of the refrigerated vaccines. and last thing, a temperature monitor. so the first thing the cdc is there was no excursion on that product. that is the program. we're ready to start shipping vaccines and ancillary supplies today. >> outstanding. the next question goes to mr. smith as well as mr. wheeler, fed ex and ups.

you heard the logistical challenges that were brought up by everyone, particularly the culturing requirements for pfizer. walk us through how each of your companies approach this problem and what steps you're doing to meet the challenges of this distribution. >> sure. happy to take that. i'll tag team it with wes. i'll start at the macro. that is who we are and what we do. this is not foreign to us. between us and ups, we move millions of vaccines every year. so we have the network capabilities, connecting 90% of the world's gdp and every zip code in american. we can stage product even ultra cold freezer, which we've been adds and ups has been adding to support some of the mrna vaccines that have those deep

frozen or ultra cold requirements. this is -- we plan for surge events every year with our customers. these healthcare companies, the manufacturers, the distributors, they're our customers. we work well together. we plan for these things every year. we jump in to action and use our networks in times of disaster relief and deliver for good as we like to say at fed ex and affected communities when that happens. so we're well-versed in planning for this. we spent a a lot of time on that. a lot of the onus on protecting the vaccine is on the packaging side. i know wes will talk a little bit to that. so i'll hand it over to you, wes. >> sure. thanks. before we talk about the packaging, i just want to -- we've been involved with the pandemic since the beginning with movement of over 20 million points of ppe in the country with china, all over the world.

we're involved through the process. then we got involved with the clinical trials. in fact, we were the principal supplier of the logistics for pfizer's clinical trial. some of that trial is still john going through the ancillary products going on. as soon as april, we started a full-time vaccine task force. started to look at all of the various components. we mapped out tens of thousands of lanes across the country, across the world. very similar to what fed ex has done to make sure that we have the capacity across united states in every single jurisdiction of the u.s., plus the world. so that's been what we've been doing to get ready for this. i think temperature control is something that is very important. we can talk about that perhaps in the next segment. >> fantastic. i didn't know if you wanted to show us now about your -- the equipment, the shipper boxes you brought. a good time to do that.

>> i'm going to ask charlton to come up. we have two boxes here. this is how pfizer's box will be shipped. pfizer has designed this package exclusively for them and for the pfizer vaccine. there's four components. it's a thermal shipper. the bottom, there's dry ice. in the middle, there's the pay load. on top, more dry ice. the very top of the box, you'll see -- you can show that here -- is a controlling device that tracks the gps location of the box and plus a thermal temperature probe that goes into the pay load to make sure the temperature at minus 70 degrees celsius is maintained throughout the journey. so this box will be ready, shipped from two locations, michigan and wisconsin. they'll come to our locations at fed ex and also at ups in louisville, kentucky. we will have all of the data that comes from this books

streaming in to our command center. we have a 24/7 command center in louisville. all the data streaming in to that box will come to us in addition to our own tracking device. this box went through a couple tests. you'll see there's a tag on here. it has multiple radios built into it. ever are -- every box has this tag. it will have that data, the pfizer data and a century device this will also be attached to every trailer load that comes out of the pfizer location and the moderna location and the mckesson location to give

real-time gps data as well as temperature and shock and light exposure. so we have three ways of tracking the data every time a shipment moves. on top of that, once this arrives at each doing center around the country, ups will be shipping dry ice to replenish the box. so this will start to sublimate, which means evaporate. we will ship dry ice, about 42 pounds, the day after. this has been something that the general has asked for, something we've designed and we're prepared to do this from louisville, kentucky and on top, we'll be manufacturing 24,000 pounds of dry ice per day. we expect the peak to be shipping 60 to 70,000 pounds of dry ice a day in total. that's how it works. >> very impressive. i'm going -- i want to get to

richard in just a second. i want him to talk about his tracking mechanisms and also with people ask me, this is the busiest shipping time of the year. it's christmas. how you doing to deal with saving the world of the pandemic and delivering at christmas at the same time? i want to get to marquette for from from thermo fisher. as the testing guy, thermo has been involved a lot making the machines that do pcr, making the full service tests in the tens of millions, tens of millions of tubes of viral transport media. we're on each other's speed deal. but you're here in a different role. you have a different company and you make a lot of the hardware to keep stuff really cold. talk about your ultra low temperature solutions and what you brought here. >> thanks for hosting the panel and all that you've done in the response to the pandemic. i'd like to thank. trump, the vice president pence and the entire administration for being in a position that we

can be talking about vaccine distribution in so few months. it's pretty amazing opportunity to do so. so thermo fisher scientific has been very involved. our microscopes used to find the spike protein. that's what the vaccine uses to target. we used our factories to produce the product and the raw materials in the product. but today when you think about vaccine distribution, it's really about ultra cold storage. in the 1950s, we started in the process of supplying laboratories with ultra low temperature freezers, minus 80, minus 86 degrees temperature freezer so you can store these vaccines and other biological samples. our team around the world is ready. in fact, we have made significant investments in our

facilities in asheville, north carolina, marietta, ohio, adding american jobs and millions in investment to be ready for this day. when we heard about operation warp speed, we started the hiring because we knew we needed to be ready so when a vaccine was ready, thermo fisher was ready. so in this ultra low temperature unit made in north carolina, effectively you can store about 5,000 doses. the typical ones, about 3,000 doses. i'll keep it safe and open it up so you get a sense of the scale of it, which is here. inside you can store the 5,000 doses. so we're ready. as the requirements are needed, we'll be there to support the efforts of the government. >> thank you very much for that. so i'm going to get back to mr. smith. let me rephrase the question. how you going to keep general

purna and santa claus happy at the same time? >> sure. some of our trucks said fed ex ground, some said fed ex express. you ship time destination critical shipments like vaccines. our ground system is where the bulk of your christmas presents and most of the online commerce serves that we've seen. that is who is out there delivering that. so running discrete networks gives us the focus and the ability to make the vaccines a priority. secondly, you touched on our tracking and monitoring solution. this is the most -- this is our patented, the latest and greatest in positive control. gives us real time visibility to every shipment we pick up. so our carriers will affix these tags to every box. the priority alert agents will be in a 24/7 , 365 command

center based on traditional scan data and the real-time data. even more importantly than that is what we call fed ex surround. its a new platform that we launched in collaboration with microsoft. it uses that da da that we generate to give us predictive analytics. so if that package is in danger of failing, they can jump in to action and intercede before a failure occurs. that's a profound leap forward in track and trace technology. it's the future. we're proud of it and we're debuting it and using it in conjunction with the vaccine distribution. >> i think we have time for a couple more questions. i'll ask generally, we know this is your business, all of you. this is what you do. did you have to do any special training for you employees, pilots, anyone in the system to

get ready for this mission? you can start with mckesson first. >> this is something that we're quite familiar with, very extensive experience in vaccines. although this is a unique environment. it's a couple things. one, the moderna vaccine given its need to be stored and distributed at negative 15, negative 25 range. we had to get equipment and specially train our employees to work and operate in that environment. we're actually taking the doses from the pallet and put it in the packages within the freezer. you can imagine. you can only do that nor a certain period of time, 15, 20, 30 minutes. other than that, the rest of the program, we're doing it at a bigger scale. >> fantastic. anyone else? >> i'll add to that. of course, we have 3,000 pilots in the u.s. we land every day and take off from louisville, kentucky.

we ship 60 million flu vaccines a year. we're very good at this. we know how to handle biologic drug. this is kept at very low temperatures. we have had to make sure that we have enough dry ice on the aircraft and how to handle the special tracking devices that i explained on the box. >> similar to wes, we work with the faa over the years to raise the threshold in terms of how much dry ice we can carry. we installed c 02 monitors and the crews are well-versed and trained for all sorts of eventualities. we have d.g. specialists that are trained in handling dry ice and dangerous goods packages. this is not new to us. just like our esteem competitor, we handle millions of shipments and bioligics that have tip control requirements every year. >> mark, anything from your

side? >> because of the ramp up of hiring, over 5,000 new employees this year in the response, the training efforts have been monumental. we have a phenomenal team and i couldn't be more grateful because it's their work that has put me on the stage. it's all of their hard efforts that has given us the opportunity to play a role in this response. >> art? >> just going to mention, in terms of scale, remember, this is a peak period for fed ex and ups. we shipped 34 million packages yesterday. so we're estimating that the number of shipments required is a very small amount. this is a small fraction of what we do every day. >> the next panel, we know this is -- the goal is to get needles in people's arms, save lives. we're going to be working with walgreen's and cvs. it would be interesting to the audience to understand what kind

of interactions you have with them daily what you've had to build. i bet thermo is supplying them to something as well. maybe we'll start weather mow and go around. >> yeah. we prepare our cold storage products to be ready to support the retailers. so we've had close contact with them. we'll supply whatever they need. >> they're our customers. we know them well. we have on-site pickup. they act as retail access points for our networks, where you can pick up and deliver your packages at walgreen's or cvs. we know their business. we go there every day. >> i think we have 10,000 cvs stores in our database. we'll be delivering starting in the next couple days. we're prepared. we're ready. we're excited about that. on behalf of the 500,000 upsers, we're excited to be part of this

operation. >> and cvs is our largest customer and we work with walgreen's. we deliver pharmaceuticals and supplies every day. we have an extensive relationship with them. >> i had great confidence by reinforces that. this is what you do, right? it's like me as a pediatrician. this is what i do every day. this is what you do. the scale is larger and the complexity is higher. but i have great confidence as the american people should. let me ask the last question. a couple of you said you might want to take this. any myths you want to bust? >> oh, man. come on. how much time do you have? >> i think i we have about five minutes left. myths to bust. i think it's very important. the rumor mills get out there. you know, the twitter machine is crazy. so let's bust some myths. >> let me start with the one that is probably the most in our

wheel house as an airline. obvious through there's others out there. there's not enough dry ice in the world, there's not enough gloves. there's not enough air cargo capacity to handle this. i've seen studies that say you need 8,000 jumbo jets, some ate 747s, 777s. different units of capacity. let's say wide body aircraft. at fed ex-, we have 32,000 flights a month. half of those are wide body aircraft. if we dedicated our network to it, we could deliver the world's vaccines, which the assumptions are flawed. but let's assume they are. but those studies, we could deliver the vaccines using just our network in a couple weeks. you don't fly an airplane just once. you fly it multiple times that is a huge myth out there. there's plenty of air cargo

capacity in our networks and our competitors to handle this. it's not all on a tuesday. it's a function of time. it comes over time. we got this. relax. it's fed ex. >> and ups. >> i've seen that myth propagated this weekend. you have one? >> i think the perception that everything travels in a temperature-controlled vehicle or aircraft is -- we have that. we do that every day with many products. in this case, these vaccines, temperature is controlled in the box. the box has been designed to maintain temperature for ten days. i didn't show this before, but that's a 2 mil vile there. we can put up to 5,000 doses in that box. so the temperature will be maintained for ten days. we will have the dry ice to replenish if necessary. this is how we do it. the myth is wrong.

>> fantastic. said it well. any myths from you? >> i just want to say, i want to thank all of you and all of your employees. when they get up in the morning, i hope when you ask them what they're doing, you know, they're not loading an aircraft. they're saving lives, thousands of lives. their contribution is as vital as anybody with a stethoscope or immunizing someone. i can just say having worked with all of your companies since they one in this pandemic, i want to thank you on behalf of the american people, our service and everyone you serve. [applause] >> bill: that was something else. hundreds of thousands of sites if necessary for distribution. ready so ship today. fed ex talking about shipping 34 million packages yesterday alone. busted myth. the head of fed ex saying we got this, relax. that continues in a moment with how the vaccines will be administered. this is a press conference that

we've been waiting for for 11 months. dr. mark, first time we've been able to get your feedback on what we're watching this past hour here. but i think you're seeing the machine of american business and american medicine merge in a way that we have never watched before, doctor. >> very impressivimpressive, bi very re-assuring. admiral girard is very straightforward. we knew the role the military was playing with general purna. here's what is new today. mckesson came forward and said here's what we do. we knew they handled vaccines and syringes and they distribute it. we knew they're number 1 in terms of medicine distribution, pharmaceuticals. they sounded very re-assuring today about how they're going to

do it and how extensive it's going to be. and then fold in fed ex and ups. as you said, they have the planes and the viles in the boxes. 5,000 viles per box. they got the boxes, temperature controlled and a program called tiberius that will monitor that temperature control. all of this is the flesh on the bones that makes america listening and watching this re-assured that it is actually going to deliver millions of doses in a safe and effective why. >> bill: it's amazing stuff here. they're taking a break inside the room right now. when they continue and resume there, we'll take our viewers back inside. you're about halfway through the program. so doctor, when you were watching them show us how the, bos were made, the companies had to work with the doctors to make sure it was safe to travel, correct? >> that's right. you know what? i wish, bill, we could go back and replay the tapes of all the naysayers back in march, april,

may who said repeatedly that it would take a year a couple years. meanwhile, marc siegel and myself were saying don't underestimate the power of the american scientific community. add mir -- admiral girard, very impressive. we got it done. a day everybody should be proud of. >> dr. marc siegel, we've had this back and forth whether or not we could have broken through this wall quicker. you know what they're doing in london. the vaccinations are being delivered. you accept that argument? >> yeah, i think yes could have dope it -- we don't know what is going on inside the fda. here's what i know. the science has preceded at an unprecedented rate and we also ponied up the manufacturing to match it. we bought 100 million doses of the pfizer vaccine, we bought 100 million doses of themer do that vaccine and that

incentivizes the process to get it built and get it done. we're talking a week or two difference here. i'm on the side it could have been a week ago. that's about it. this is unbelievably quick historically. but also safe. also effective. we never thought it would going to be a 95% effective vaccine. 95% coming out of the starting gate. that's like the measles vaccine. nobody thought that. >> bill: 30 to 60 on the flu. stand by. a lot of reporting across the country. here's california. millions under the stay-at-home restrictions for three weeks. some business owners fear this could put them out of business. william la jeunesse is tracking their story in santa monica. what did you find out? >> you know, bill, some retailers will make half a year's income back thanksgiving and christmas. the governor's stay-at-home hoarders have flat-lined sales. the mayor said hunker down, stay

home. get it on your phone every day. monday governor newsome saying no indoor or outdoor dining. stores limiting capacity at 20% that is flat-line sales and killing foot traffic. some people are required to limit their capacity to four customers. they're in the allowed in the stores. many are already out of business here and others are struggling under the new rules. >> it's our entire year sales. we depend on this time of year to keep us in business. we depend on this time of year to make us thrive. this is where we stake our ground. we spend our year planning for this time of year. it's devastating to our business. >> we're a gift shop. like those three weeks of december is where we make any money we're going to make in a year. you know, i lived in terror in november that we would get shut down entirely. >> asked if you had any ed to support the cap, governor

newsome offered this. >> yeah, i said it friday, i said it monday. i'll say it again today. i'm deeply committed to supporting our small businesses in this trying and challenging time. >> the biggest problem here, bill, is not just a shortage of beds but staff. about 1,700 healthcare workers in l.a. contracted the virus last week alone. so the vaccine cannot come soon enough for healthcare workers. >> bill: thanks, william. i want to bring back in the experts. doctors, in 90 seconds i have left here. as i look at the schedule for this week, the fda conducts its hearing in two days. in all likelihood after that concludes, we could be vaccinating americans by saturday. that sound about right? >> it could be friday. could be thursday night. we are seeing a lot of interest

right now and the fda putting their answer down quickly. this is a redemption story for mckesson as well. they're the largest distributor of medication. they had a hand in the opioid epidemic. it's been well-documented. they were distributing opioids to tiny clinics. this is a story of redemption. a good story. finally, people don't want to get the infection in the last three months of this pandemic. we have had a massive sacrifice that's been made. try not to get the infection in the last two or three months. >> dr. marc siegel, final thought there. >> we predicted this day. my final message is to our healthcare workers. take the vaccine to protect you, your patients and to send a message to america. everyone take this vaccine. >> bill: thanks, doctor. great to get your expertise. gentlemen, thank you. onward we roll, a break during this hearing at the white house.

we'll talk about the vaccines and then the roll of jurisdictions. a lot of governors from different parts of the country. so stand by. it's a good news day as we like to say. see you tomorrow at 3:00 eastern. meantime, on to "your world" we roll. here's neil. >> neil: thank you, bill. we're monitoring these developments at the white house as well. operation warp speed and the vaccine summit continues. we'll be going back to that. we want to let you know that the markets were encouraged by the things that were being said at that summit and the likelihood that as you said, bill, americans could have this as soon as the next couple days. the fda gives the strongest signal yet that it's going to write off on the pfizer and moderna seen with signs that come next week, the same advisory will write off on the moderna vaccine. this coming at a time that we're learning the first patients are getting the first shots, two of them startin